AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer

European Journal of Pharmacology

Volumn 766, Issue , 2015, Pages 63-75

  Kobayashi, Aya ^a   Tanizaki, Yuko ^a   Kimura, Akihiko ^a   Ishida, Yuko ^a   Nosaka, Mizuho ^a   Toujima, Saori ^a   Kuninaka, Yumi ^a   Minami, Sawako ^a   Ino, Kazuhiko ^a   Kondo, Toshikazu ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Immune tolerance; Immunotherapy; JAK STATsignal; Ovariancancer; Peritoneal dissemination

Indexed keywords

GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; JANUS KINASE 2; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT1 PROTEIN; ALPHA-CYANO-(3,4-DIHYDROXY)-N-BENZYLCINNAMIDE; CYTOKINE; JAK2 PROTEIN, MOUSE; STAT1 PROTEIN, MOUSE; TYRPHOSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IDO GENE; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; SURVIVAL RATE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYTOKINES; FEMALE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; JANUS KINASE 2; MICE; OVARIAN NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; TYRPHOSTINS;

EID: 84944751191     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2015.09.039     Document Type: Article

References (49)

1. V. Aumiller, N. Balsara, J. Wilhelm, A. Gunther, and M. Konigshoff WNT/ß-catenin signaling induces IL-1beta expression by alveolar epithelial cells in pulmonary fibrosis Am. J. Respir. Cell Mol. Biol. 49 2013 96 104
2. F. Balkwill TNF-α in promotion and progression of cancer Cancer Metastasis Rev. 25 2006 409 416
3. C.G. Caraguel, H. Stryhn, N. Gagne, I.R. Dohoo, and K.L. Hammell Selection of a cutoff value for real-time polymerase chain reaction results to fit a diagnostic purpose: analytical and epidemiologic approaches J. Vet. Diagn. Investig. 23 2011 2 15
4. L.C. Chen, L.J. Wang, N.M. Tsang, D.M. Ojcius, C.C. Chen, C.N. Ouyang, C. Hsueh, Y. Liang, K.P. Chang, C.C. Chen, and Y.S. Chang Tumour inflammasome-derived IL-1beta recruits neutrophils and improves local recurrence-free survival in EBV-induced nasopharyngeal carcinoma EMBO Mol. Med. 4 2012 1276 1293
5. C.M. Coughlin, K.E. Salhany, M.S. Gee, D.C. LaTemple, S. Kotenko, X. Ma, G. Gri, M. Wysocka, J.E. Kim, L. Liu, F. Liao, J.M. Farber, S. Pestka, G. Trinchieri, and W.M. Lee Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis Immunity 9 1998 25 34
6. T.J. Curiel, G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, M. Evdemon-Hogan, J.R. Conejo-Garcia, L. Zhang, M. Burow, Y. Zhu, S. Wei, I. Kryczek, B. Daniel, A. Gordon, L. Myers, A. Lackner, M.L. Disis, K.L. Knutson, L. Chen, and W. Zou Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat. Med. 10 2004 942 949
7. M. Della Chiesa, S. Carlomagno, G. Frumento, M. Balsamo, C. Cantoni, R. Conte, L. Moretta, A. Moretta, and M. Vitale The tryptophan catabolite l-kynurenine inhibits the surface expression of NKp46- and NKG2d-activating receptors and regulates NK-cell function Blood 108 2006 4118 4125
8. A. Desmouliere, C. Guyot, and G. Gabbiani The stroma reaction myofibroblast: a key player in the control of tumor cell behavior Int. J. Dev. Biol. 48 2004 509 517
9. G. dos Santos, M.A. Kutuzov, and K.M. Ridge The inflammasome in lung diseases Am. J. Physiol. Lung Cell. Mol. Physiol. 303 2012 L627 L633
10. J.E. Durbin, R. Hackenmiller, M.C. Simon, and D.E. Levy Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease Cell 84 1996 443 450
11. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr. Rev. 25 2004 581 611
12. S. Fujigaki, K. Saito, K. Sekikawa, S. Tone, O. Takikawa, H. Fujii, H. Wada, A. Noma, and M.F. Seishima Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism Eur. J. Immunol. 31 2001 2313 2318
13. H. Fujigaki, K. Saito, S. Fujigaki, M. Takemura, K. Sudo, H. Ishiguro, and M. Seishima The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines J. Biochem. 139 2006 655 662
14. T.F. Gajewski Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment Clin. Cancer Res. 12 2006 2326s 2330s
15. J. Godin-Ethier, L.A. Hanafi, C.A. Piccirillo, and R. Lapointe Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives Clin. Cancer Res. 17 2011 6985 6991
16. J. Guo, N. Gu, J. Chen, T. Shi, Y. Zhou, Y. Rong, T. Zhou, W. Yang, X. Cui, and W. Chen Neutralization of interleukin-1 beta attenuates silica-induced lung inflammation and fibrosis in C57BL/6 mice Arch. Toxicol. 87 2013 1963 1973
17. L.M. Hix, J. Karavitis, M.W. Khan, Y.H. Shi, K. Khazaie, and M. Zhang Tumor STAT1 transcription factor activity enhances breast tumor growth and immune suppression mediated by myeloid-derived suppressor cells J. Biol. Chem. 288 2013 11676 11688
18. T. Inaba, K. Ino, H. Kajiyama, E. Yamamoto, K. Shibata, A. Nawa, T. Nagasaka, H. Akimoto, O. Takikawa, and F. Kikkawa Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma Gynecol. Oncol. 115 2009 185 192
19. Y. Ishida, A. Kimura, Y. Kuninaka, M. Inui, K. Matsushima, N. Mukaida, and T. Kondo Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing J. Clin. Invest. 12 2012 711 721
20. I.D. Jung, C.M. Lee, Y.I. Jeong, J.S. Lee, W.S. Park, J. Han, and Y.M. Park Differential regulation of indoleamine 2,3-dioxygenase by lipopolysaccharide and interferon gamma in murine bone marrow derived dendritic cells FEBS Lett. 581 2007 449 1456
21. J.B. Katz, A.J. Muller, and G.C. Prendergast Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape Immunol. Rev. 222 2008 206 221
22. E. Koga-Yamakawa, S.J. Dovedi, M. Murata, H. Matsui, A.J. Leishman, J. Bell, D. Ferguson, S.P. Heaton, T. Oki, H. Tomizawa, A. Bahl, H. Takaku, R.W. Wilkinson, and H. Harada Intratracheal and oral administration of SM-276001: a selective TLR7 agonist, leads to antitumor efficacy in primary and metastatic models of cancer Int. J. Cancer. 132 2013 580 590
23. N. Leffers, M.J. Gooden, R.A. de Jong, B.N. Hoogeboom, K.A. ten Hoor, H. Hollema, H.M. Boezen, A.G. van der Zee, T. Daemen, and H.W. Nijman Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer Cancer Immunol. Immunother. 58 2009 449 459
24. Y. Li, E.E. Tredget, A. Ghaffari, X. Lin, R.T. Kilani, and A. Ghahary Local expression of indoleamine 2,3-dioxygenase protects engraftment of xenogeneic skin substitute J. Invest. Dermatol. 126 2006 128 136
25. C.Z. Liu, L. Zhang, X.H. Chang, Y.X. Cheng, H.Y. Cheng, X. Ye, T.Y. Fu, J. Chen, and H. Cui Overexpression and immunosuppressive functions of transforming growth factor 1, vascular endothelial growth factor and interleukin-10 in epithelial ovarian cancer Chin. J. Cancer Res. 24 2012 130 137
26. C.R. MacKenzie, K. Heseler, A. Muller, and W. Daubener Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines Curr. Drug Metab. 8 2007 237 244
27. A.L. Mellor, and D.H. Munn IDO expression by dendritic cells: tolerance and tryptophan catabolism Nat. Rev. Immunol. 4 2004 762 774
28. D.H. Munn, and A.L. Mellor Indoleamine 2,3-dioxygenase and tumor-induced tolerance J. Clin. Invest. 117 2007 1147 1154
29. H. Nonaka, Y. Saga, H. Fujiwara, H. Akimoto, A. Yamada, S. Kagawa, Y. Takei, S. Machida, O. Takikawa, and M. Suzuki Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killer cell function and angiogenesis promotion Int. J. Oncol. 38 2011 113 120
30. I. Puisieux, L. Odin, D. Poujol, P. Moingeon, J. Tartaglia, W. Cox, and M. Favrot Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity Hum. Gene Ther. 9 1998 2481 2492
31. S.A. Sarkar, R. Wong, S.I. Hackl, O. Moua, R.G. Gill, A. Wiseman, H.W. Davidson, and J.C. Hutton Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets Diabetes 56 2007 72 79
32. J. Schultz, D. Koczan, U. Schmitz, S.M. Ibrahim, D. Pilch, J. Landsberg, and M. Kunz Tumor-promoting role of signal transducer and activator of transcription (Stat)1 in late-stage melanoma growth Clin. Exp Metastasis 27 2010 133 140
33. A. Sica, P. Larghi, A. Mancino, L. Rubino, C. Porta, M.G. Totaro, M. Rimoldi, S.K. Biswas, P. Allavena, and A. Mantovani Macrophage polarization in tumour progression Semin. Cancer Biol. 18 2008 349 355
34. Y.F. Song, H.C. Feng, L. Tang, J.F. Peng, and H. Ma Experimental study on the anti-tumor effect of monocytes/macrophages against Tca8113 cells and the secretion of vascular endothelial growth factor in acid microenvironment Hua Xi Kou Qiang Yi Xue Za Zhi 28 2010 364 366
35. Y. Suzuki, T. Suda, K. Furuhashi, M. Suzuki, M. Fujie, D. Hahimoto, Y. Nakamura, N. Inui, H. Nakamura, and K. Chida Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer Lung Cancer 67 2010 361 365
36. Y. Takei, M. Suzuki, M. Ohwada, Y. Saga, T. Kohno, S. Machida, and Sato A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer Oncol. Rep. 10 2003 951 955
37. O. Takikawa Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism Biochem. Biophys. Res. Commun. 338 2005 12 19
38. Y. Tanizaki, A. Kobayashi, S. Toujima, M. Shiro, M. Mizoguchi, Y. Mabuchi, S. Yagi, S. Minami, O. Takikawa, and K. Ino Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by inducing an immunosuppressive environment Cancer Sci. 105 2014 966 973
39. S.W. Tas, M.J. Vervoordeldonk, N. Hajji, J.H. Schuitemaker, K.F. van der Sluijs, M.J. May, S. Ghosh, M.L. Kapsenberg, P.P. Tak, and E.C. de Jong Noncanonical NF-kappaB signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation Blood 110 2007 1540 1549
40. M.W. Taylor, and G.S. Feng Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism FASEB J. 5 1991 2516 2522
41. G. Trinchieri Interleukin-12: a cytokine at the interface of inflammation and immunity Adv. Immunol. 70 1998 83 243
42. E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini Functions of natural killer cells Nat. Immunol. 9 2008 503 510
43. E. Voronov, S. Dotan, Y. Krelin, X. Song, M. Elkabets, Y. Carmi, P. Rider, Idan Cohen, M. Romzova, I. Kaplanov, and R.N. Apte Unique Versus Redundant Functions of IL-1alpha and IL-1beta in the Tumor Microenvironment Front Immunol. 4 2013 177
44. D.A. Wainwright, I.V. Balyasnikova, A.L. Chang, A.U. Ahmed, K.S. Moon, B. Auffinger, A.L. Tobias, Y. Han, and M.S. Lesniak IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival Clin. Cancer Res. 18 2012 6110 6121
45. D. Wang, Y. Saga, H. Mizukami, N. Sato, H. Nonaka, H. Fujiwara, Y. Takei, S. Machida, O. Takikawa, K. Ozawa, and M. Suzuki Indoleamine-2,3-dioxygenase, an immunosuppressive enzyme that inhibits natural killer cell function, as a useful target for ovarian cancer therapy Int. J. Oncol. 40 2012 929 934
46. T.L. Whiteside Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention Semin. Cancer Biol. 16 2006 3 15
47. M.R. Zaidi, and G. Merlino The two faces of interferon-gamma in cancer Clin. Cancer Res. 17 2011 6118 6124
48. J. Yu, J. Sun, S.E. Wang, H. Li, S. Cao, Y. Cong, J. Liu, and X. Ren Upregulated expression of indoleamine 2,3-dioxygenase in primary breast cancer correlates with increase of infiltrated regulatory T cells in situ and lymph node metastasis Clin. Dev. Immunol. 469 2011 135
49. J.W. Zhou, Q. Cheng, X. Xie, H.Z. Chen, D.F. Ye, and W.G. Lu Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity Ai Zheng 23 2004 573 576